Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: a multisampling algorithm-based structural study
- PMID: 37058176
- DOI: 10.1007/s11030-023-10648-0
Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: a multisampling algorithm-based structural study
Abstract
Lung cancer is the second most common cancer, which is the leading cause of cancer death worldwide. The FDA has approved almost 100 drugs against lung cancer, but it is still not curable as most drugs target a single protein and block a single pathway. In this study, we screened the Drug Bank library against three major proteins- ribosomal protein S6 kinase alpha-6 (6G77), cyclic-dependent protein kinase 2 (1AQ1), and insulin-like growth factor 1 (1K3A) of lung cancer and identified the compound 5-nitroindazole (DB04534) as a multitargeted inhibitor that potentially can treat lung cancer. For the screening, we deployed multisampling algorithms such as HTVS, SP and XP, followed by the MM\GBSA calculation, and the study was extended to molecular fingerprinting analysis, pharmacokinetics prediction, and Molecular Dynamics simulation to understand the complex's stability. The docking scores against the proteins 6G77, 1AQ1, and 1K3A were - 6.884 kcal/mol, - 7.515 kcal/mol, and - 6.754 kcal/mol, respectively. Also, the compound has shown all the values satisfying the ADMET criteria, and the fingerprint analysis has shown wide similarities and the water WaterMap analysis that helped justify the compound's suitability. The molecular dynamics of each complex have shown a cumulative deviation of less than 2 Å, which is considered best for the biomolecules, especially for the protein-ligand complexes. The best feature of the identified drug candidate is that it targets multiple proteins that control cell division and growth hormone mediates simultaneously, reducing the burden of the pharmaceutical industry by reducing the resistance chance.
Keywords: 5-Nitroindazole; Molecular dynamics simulation; Molecular fingerprints; Multitargeted docking; WaterMap.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Variolin B from sea sponge against lung cancer: a multitargeted molecular docking with fingerprinting and molecular dynamics simulation study.J Biomol Struct Dyn. 2024 Apr;42(7):3507-3519. doi: 10.1080/07391102.2023.2272204. Epub 2023 Oct 19. J Biomol Struct Dyn. 2024. PMID: 37855303
-
Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: an optimisation followed multi-simulation and in-vitro study.J Biomol Struct Dyn. 2024 Mar;42(5):2494-2511. doi: 10.1080/07391102.2023.2209673. Epub 2023 May 8. J Biomol Struct Dyn. 2024. PMID: 37154501
-
Unveiling the multitargeted potency of Sodium Danshensu against cervical cancer: a multitargeted docking-based, structural fingerprinting and molecular dynamics simulation study.J Biomol Struct Dyn. 2024 Oct;42(16):8268-8280. doi: 10.1080/07391102.2023.2248260. Epub 2023 Aug 20. J Biomol Struct Dyn. 2024. PMID: 37599470
-
Molecular screening reveals Variolin B as a multitargeted inhibitor of lung cancer: a molecular docking-based fingerprinting and molecular dynamics simulation study.J Biomol Struct Dyn. 2024 Jan-Feb;42(1):11-21. doi: 10.1080/07391102.2023.2263560. Epub 2023 Dec 28. J Biomol Struct Dyn. 2024. PMID: 37771142
-
Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer.Med Oncol. 2024 Mar 28;41(5):101. doi: 10.1007/s12032-024-02342-4. Med Oncol. 2024. PMID: 38546811
Cited by
-
Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.In Silico Pharmacol. 2023 Dec 24;12(1):5. doi: 10.1007/s40203-023-00178-w. eCollection 2024. In Silico Pharmacol. 2023. PMID: 38148755 Free PMC article.
-
Identification of an Exosome-relevant SNHG6-hsa-miR-429- CHRDL1/CCNA2 Axis for Lung Adenocarcinoma Prognosis Evaluation.Curr Med Chem. 2024;31(28):4549-4561. doi: 10.2174/0109298673280925231122104717. Curr Med Chem. 2024. PMID: 38994652
-
Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor.Pharmaceuticals (Basel). 2024 Feb 6;17(2):208. doi: 10.3390/ph17020208. Pharmaceuticals (Basel). 2024. PMID: 38399423 Free PMC article.
-
Systems biology approach: identification of hub genes, signaling pathways, and molecular docking of COL1A1 gene in cervical insufficiency.In Silico Pharmacol. 2024 May 14;12(1):45. doi: 10.1007/s40203-024-00218-z. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38756679
-
Delineated 3-1-BenCarMethInYlPro-Phosphonic Acid's Adroit Activity against Lung Cancer through Multitargeted Docking, MM\GBSA, QM-DFT and Multiscale Simulations.Int J Mol Sci. 2024 Jan 2;25(1):592. doi: 10.3390/ijms25010592. Int J Mol Sci. 2024. PMID: 38203761 Free PMC article.
References
-
- Organization WH. WHO report on cancer: setting priorities, investing wisely and providing care for all. 2020. https://www.who.int/publications/i/item/9789240001299 .
-
- Organization WH. Gender in lung cancer and smoking research. 2004. https://apps.who.int/iris/handle/10665/43086 .
-
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149(4):778–789. https://doi.org/10.1002/ijc.33588 - DOI
-
- Sharma R (2022) Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol 27(4):665–675. https://doi.org/10.1007/s10147-021-02108-2 - DOI - PubMed - PMC
-
- Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1(1):49–52. https://doi.org/10.1016/S1535-6108(02)00027-2 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical